Targeting a Single Function of the Multifunctional Matrix Metalloprotease MT1-MMP

IMPACT ON LYMPHANGIOGENESIS*

Received for publication, December 19, 2012, and in revised form, February 4, 2013. Published, JBC Papers in Press, February 14, 2013, DOI 10.1074/jbc.M112.447169

Signe Ingvarsen1,2, Astrid Porse1,2, Charlotte Erpicum1, Ludovic Maertens3, Henrik J. Jürgensen4, Daniel H. Madsen1, Maria C. Melander1, Henrik Gårdsvoll5, Gunilla Hoyer-Hansen6, Agnès Noel7, Kenn Holmbeck8, Lars H. Engelholm9, and Niels Behrendt10

From the 1Finsen Laboratory, Rigshospitalet/BRIC, DK-2200 Copenhagen N, Denmark, the 2Department of Biology, University of Copenhagen, DK-2200 Copenhagen N, Denmark, the 3Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège, B-4000 Liège, Belgium, and the 4Craniofacial and Skeletal Diseases Branch, NIDCR, National Institutes of Health, Bethesda, Maryland 20892

Background: Therapeutic strategies for MMP targeting have limited selectivity.

Results: A novel, specific mAb against MT1-MMP selectively blocks proMMP-2 activation. This antibody inhibited lymphatic vessel sprouting.

Conclusion: A single function of a multifunctional MMP was blocked selectively and completely. MT1-MMP mediated proMMP-2 activation is involved in lymphangiogenesis.

Significance: This supports development of therapeutic MMP targeting and the understanding of lymphangiogenesis.

The group of matrix metalloproteases (MMPs) is responsible for multiple processes of extracellular matrix remodeling in the healthy body but also for matrix and tissue destruction during cancer invasion and metastasis. The understanding of the contributions from each individual MMP, both in healthy and pathological events, has been complicated by the lack of specific inhibitors and the fact that some of the potent MMPs are multifunctional enzymes. These factors have also hampered the setup of therapeutic strategies targeting MMP activity. A tempting target is the membrane-associated MT1-MMP, which has well-documented importance in matrix degradation but which takes part in more than one pathway in this regard. In this report, we describe the selective targeting of a single function of this enzyme by means of a specific monoclonal antibody against MT1-MMP, raised in an MT1-MMP knock-out mouse. The antibody blocks the enzyme ability to activate proMMP-2 without interfering with the collagenolytic function or the general proteolytic activity of MT1-MMP. Using this antibody, we have shown that the MT1-MMP-catalyzed activation of proMMP-2 is involved in the outgrowth of cultured lymphatic endothelial cells in a collagen matrix in vitro, as well as in lymphatic vessel sprouting assayed ex vivo. This is the first example of the complete inactivation of a single function of a multifunctional MMP and the use of this strategy to pursue its role.

Matrix metalloproteases (MMPs) are centrally engaged in the processes of extracellular matrix (ECM) turnover that occur both during normal development and in connection with various pathological conditions, including cancer growth, invasion, and metastasis (1). MT1-MMP (MMP-14), a transmembrane type MMP, plays a critical role in pericellular collagen remodeling (2, 3) and MT1-MMP-deficient mice have a profound phenotype including defective angiogenesis and severe bone defects, associated with inadequate collagen turnover (2, 4). The human correlate of these bone defects is known as the Winchester syndrome (5) and is associated with mutations in MT1-MMP (6). The collagen degrading properties of MT1-MMP include both a direct collagenolytic activity and the ability to activate proMMP-2, the proform of the secreted gelatinase MMP-2 (4, 7–9), but the relative importance of these activities remains elusive. Mutations in the human MMP-2 gene give rise to severe bone disorders (10) and although ablation of the gene in mice was initially reported only to result in minor growth impairments (11), detailed analyses have revealed that MMP-2-deficient mice share many of the characteristics of the human disease in an attenuated form (12, 13). In mice expressing a mutated collagen, modified in the classical...
collagenase cleavage site, concomitant MMP-2 deficiency was shown to severely impact skeletal development (14). This implicates the enzyme in bulk turnover of matrix components in the skeleton. Furthermore, recent studies have pointed to an important function of MMP-2 in lymphangiogenesis, the sprouting of lymphatic vessels (15, 16).

Both MT1-MMP and MMP-2 have been tightly linked to tumorigenesis. Both enzymes are highly expressed in human cancers where the levels of MT1-MMP expression and active MMP-2 are positively correlated (17, 18) and in mouse cancer models, both proteins contribute to several stages of disease progression (19–24). Thus, it is likely that the role of MT1-MMP in cancer progression includes both direct collagen cleavage and activation of proMMP-2.

Monoclonal antibodies (mAbs) are valuable reagents for the specific functional targeting of extracellular and membrane-bound proteins and have been used successfully in studies of protein function in vivo (25–27), as well as for therapeutic targeting in vitro (28). Importantly, a function blocking anti-MT1-MMP mAb has been developed by phage display technology. This antibody is capable of decreasing tumor growth, angiogenesis, and invasion in vivo (19). However, since it acts as a general inhibitor of MT1-MMP proteolytic activity, it does not allow a distinction between the individual roles of MT1-MMP. To this end, another highly interesting mAb was developed recently and shown to interfere specifically with the collagen binding activity of the MT1-MMP hemopexin domain. This latter antibody was found to counteract MT1-MMP-dependent collagen degradation and, even though the anti-collagenolytic effect was incomplete, it also strongly attenuated cellular invasion in vitro (29).

In the present work, we have succeeded in developing an MT1-MMP mAb that selectively inhibits the other major function, i.e. proMMP-2 activation, with no effect on the general proteolytic or the collagenolytic activity of MT1-MMP. This blocking effect is complete, thus enabling the selective targeting of a single function of the enzyme. Furthermore, using this antibody, we have shown the importance of MT1-MMP mediated proMMP-2 activation in the sprouting of lymphatic microvessels in a collagen matrix.

**EXPERIMENTAL PROCEDURES**

**Cells, Reagents, and Antibodies**—The following cells, mAbs, and reagents have been described previously or were purchased from commercial sources: Primary murine skin fibroblasts (25), human HT1080 cells and Chinese Hamster Ovary (CHO) cells (ATCC), mAb against trinitrophenyl functional group (a-TNP) (30), murine mAb-2 against MT1-MMP (25), Galardin/GM6001 (31), rat-tail collagen type I (trypsin-resistant collagen I (BD Biosciences) for fibroblast mediated degradation studies (25) and pepsin-extracted collagen (collagen R; Serva electrophoresis) for lymphatic endothelial cell sprouting analyses (16)), recombinant human MT1-MMP for BIAcore analyses (complete extracellular part of the enzyme; Calbiochem), interleukin 1β (IL-1β), and tumor necrosis factor-α (TNF-α) (Peprotech) and recombinant human TIMP-2 (Fuji Chemical Industries). Recombinant human TIMP-1 was a kind gift from Professor Gillian Murphy, Cambridge Research Institute, UK. BIAcore chips, reagents, and rabbit-anti-mouse IgG capture antibody for surface plasmon resonance studies were from GE Healthcare. Novel mAbs against MT1-MMP were generated as described below.

**Recombinant MT1-MMP Construct for Immunization of Mice**—A recombinant, truncated MT1-MMP protein, comprising the propeptide and the catalytic domain of murine MT1-MMP (Gln-29—Ser-289) and a C-terminal 6-histidine tag, was produced in Pichia pastoris. Construction of the expression vector (including a yeast α-factor signal sequence and a Kex2 signal cleavage site), transfection of *P. pastoris* strain X-33 cells and protein production were performed as described (32, 33), except for the following modifications: The murine MT1-MMP sequence was amplified by PCR using the pMTC/MT1-MMP/suPAR-DIII expression vector (25) as template and the following synthetic oligonucleotide primers (restriction sites underscored): 5’-TCTCTCGAGAAAA-GACAAGGCAGCAACTTCAGCC-3’ (forward primer including a Xhol restriction site) and 5’-GGCTCTAGATCAATGATGATGATGATGATGCC-3’ (reverse primer including sequence encoding the histidine tag, a stop codon, and a Xbal restriction site). The PCR product was then digested with the indicated restriction enzymes and inserted into the Pichia expression vector pPICZaaA. After transfection and isolation of a strongly producing clone, large-scale culture of cells was performed at pH 6.0, followed by harvest of the supernatant after 24 h. The protein product, designated MT1-MMP29–289-His, was purified from the filtered supernatant using a 1 ml HisTrap HP column (GE Healthcare) and elution with a linear imidazole gradient ranging from 0.01–1 M imidazole in 20 mM sodium phosphate, 300 mM NaCl, pH 7.0.

**CHO Cells Transfected with MT-MMPs**—For the construction of expression vectors encoding murine MT1-MMP, MT2-MMP, or MT3-MMP, the respective sequences (34) were cloned into the pWPI GW vector. This vector was modified from the pWPI GW vector (35) by the inclusion of a separate sequence encoding the GFP homolog dsRED (36) to allow an evaluation of transfection efficiency. CHO cells were transiently transfected with these vectors using Lipofectamine 2000. Uniform transfection levels were confirmed by Western blotting of cell lysates (see below) with a goat dsRED antibody (Santa Cruz Biotechnology).

**Generation of Monoclonal Antibodies against MT1-MMP**—Immunization of young MT1-MMP-deficient mice (2) in a mixed genetic background was performed according to the previously published schedule (25), except that the mice received the first immunization injection at an age between 21 and 28 days and that each injection included 20 μg of recombinant MT1-MMP29–289-His protein mixed with either adjuvant (1 mg Al(OH)₃, Statens Serum Institut, Copenhagen, Denmark; two initial immunization injections) or PBS (subsequent three booster injections). Immunization was performed with the approval of the National Institute of Dental and Craniofacial Research (NIDCR) Animal Use and Care Committee, NIH. Sera from the immunized mice were tested for anti-MT1-MMP antibodies by ELISA (see below). Spleen cells from an antibody-positive mouse were fused with X63.Ag8.653 myeloma cells (ATCC #CRL-1580) by electrofusion, using equipment and
reagents from Cyto Pulse Sciences Inc. and following the procedures recommended by this manufacturer. Fused cells were plated in 96-well cell culture plates at a cell density of $1.5 \times 10^4$ cells/well and selection of successfully fused hybridoma cells was performed by cell culture in the presence of 100 μM hypoxanthine, 0.4 μM aminopterin, and 16 μM thymidine (HAT, Sigma-Aldrich, cat. no H0262). After 10 days of cell culture, culture supernatants were screened by ELISA, performed as described (25), except that the ELISA wells were coated with 15 ng of recombinant murine MT1-MMP29–289-His protein. Clones producing antibody reactive with MT1-MMP were subcloned by limiting dilution and the reactivity of monoclonal antibodies against MT1-MMP was confirmed by Western blot analysis. IgG was purified from the culture supernatants by affinity chromatography on a Protein G column (GE Healthcare). All mAbs were of the IgG1 subtype, as determined using a mouse monoclonal isotyping kit (SeroTec).

**Assays for Antibody Binding and Specificity**—Detergent cell lysates for Western blotting were prepared using a lysis buffer including 1% Triton X-100, 10 mM Tris/HCl, 140 mM NaCl, pH 7.4, supplemented with 0.5% (v/v) protease inhibitor mixture III (Calbiochem). Cells were incubated at 0 °C in this buffer for 20 min, followed by clarification by centrifugation. For transfected cells, this was done 24 h post-transfection. Western blotting was performed using the NuPAGE system from Invitrogen with electrophoresis on 4–12% gradient gels under reducing conditions. After electroblotting, blocking of PVDF membranes with 5% skim milk powder and incubation with murine primary antibodies in the presence of the same blocking solution, the rabbit anti-mouse IgG based chemiluminescence (ECL) system (GE Healthcare) was used for detection.

Surface plasmon resonance analysis of the binding of MT1-MMP to mAb 9E8 was done using a BIAcore 3000 instrument (GE Healthcare) and software from the same supplier. The BIAcore rabbit anti-mouse capturing antibody, coupled on a CM5 sensor chip, was used for capture of injected mAb in a uniform orientation (37). Following the binding of mAb 9E8 on this support, dilution series of purified, recombinant human MT1-MMP in 10 mM HEPES, 150 mM NaCl pH 7.4 with 0.005% Surfactant P20 (HBS-EP buffer; GE Healthcare) were injected at a flow rate of 10 μl/min, after which the binding and dissociation phases were recorded at 20 °C. A reference flow channel without coupled antibody allowed for buffer bulk subtraction throughout each sensogram. For each dilution of MT1-MMP, a parallel run was performed without pre-injection of mAb 9E8. The resulting sensogram, representing unspecific binding to the capture support, was subtracted from the specific binding curve. Kinetic analysis was performed using the BIAeval software, version 4.1. Data were analyzed according to a Langmuir 1:1 binding model, which was consistent with the curves obtained.

**Assays for MT1-MMP Function and Inhibition**—Fluorogenic assays for MT1-MMP endopeptidase (general proteolytic) activity in a purified system were performed with the recombinant murine MT1-MMP catalytic domain (see above), using the quenched fluorescent peptide substrate Mca-K-P-L-G-L-Dpa-A-R-NH$_2$ (R&D systems). The assay was performed in 100 mM Tris-HCl, 100 mM NaCl, 10 mM CaCl$_2$, 1 μM ZnCl$_2$, 0.05% Brij35, pH 7.5, including 10 μM substrate. About 5 nM MT1-MMP29–289-His was pre-incubated in the presence or absence of potential inhibitors (galardin, mAb 9E8 or TIMP-2). Assay was performed at 25 °C and fluorescence recorded continuously during a 50-min period with excitation at 355 nm and emission at 460 nm.

Studies of cell-mediated proMMP-2 activation were performed with HT1080 cells cultured in serum-free DMEM including 100 nM phorbol-12-myristate-13-acetate (PMA). Cells were cultured for 48 h in this medium alone or in the presence of potential inhibitors (galardin, TIMP-1, TIMP-2, antibodies against MT1-MMP or a-TNP (isotype-matched control antibody)). Conditioned media were then analyzed by gelatin zymography (25), using gels and reagents from Invitrogen and following the procedures recommended by the manufacturer.

Assays for fibroblast-mediated degradation of a reconstituted collagen I matrix, with cell culture in serum-free medium including 1 nM IL-1β and 10 nM TNF-α, were performed essentially as described (2). In some experiments, 125I-labeled collagen I was incorporated into the collagen matrix (26), after which the release of radiolabeled collagen degradation products was monitored daily by measuring 10 μl of culture supernatant in a gamma counter.

**Outgrowth of Lymphatic Endothelial Cells and Microvessels in Collagen Matrices**—Studies of the outgrowth of lymphatic endothelial-like HTERT-HDLEC cells (38) from collagen-embedded spheroid cultures were performed essentially as described (16). Briefly, cells were seeded and pre-cultured in endothelial basal medium (EBM)-2 containing 0.24% high viscosity methyl cellulose (Sigma Aldrich) in cell culture plates with 2 × 10³ cells per well for 24 h to form micro-spheres. Subsequently, spheroids were collected, embedded in collagen gels and maintained at 37 °C for another 24 h in medium including 5% FCS, supplemented with 650 nM anti-MT1-MMP mAb 9E8 or irrelevant control antibody (anti-TNP), using duplicate samples for each experimental condition. After this, unstained cell samples were examined by phase-contrast microscopy, using an Axiosvert 25 microscope equipped with a 20× NA 0.3 LD A-Plan lens and an AxioCam color digital camera (Carl Zeiss, Zaventem, Belgium). Images were captured at room temperature, using acquisition software KS400 3.0. Cell migration was then quantified by a computerized method determining the sprouting envelope area, defined as the area of the minimal convex polygon containing the whole spheroid and all sprouting cells. Two independent experiments were performed with identical results.

Lymphatic “ring” assays for ex vivo studies on lymphatic sprouting in a three-dimensional collagen matrix were performed as described (15). The explants of murine thoracic ducts (duplicate samples for each experimental condition) were cultured for 11 days in the presence of 650 nM mAb 9E8 or the above-mentioned irrelevant control antibody. Cultures were examined by phase contrast microscopy as above, using a 5× NA 0.12 A-Plan lens (Carl Zeiss) for image capture. Computerized quantification was based on binary images as described (15), using a grid comprised of concentric rings which was generated by successive increments at fixed intervals from the duct
Targeting MT1-MMP

RESULTS

Generation of Murine Monoclonal Antibodies against Murine and Human MT1-MMP—To obtain reagents that interfere with the individual molecular functions of MT1-MMP, a panel of mAbs against it was generated. This was achieved by immunization of MT1-MMP-deficient mice with a recombinant murine MT1-MMP protein comprising the pro-peptide and the catalytic domain (see “Experimental Procedures”). A panel of eight anti-MT1-MMP mAbs was obtained.

One of the antibodies directed against the catalytic domain, mAb 9E8 (IgG1κ subtype), was further characterized. This antibody specifically recognized MT1-MMP (Fig. 1). Thus, when lysates of wildtype and MT1-MMP-deficient primary fibroblasts were analyzed by Western blotting using this antibody, the deficient cells showed no reaction (lane 1), whereas a 55 kDa band, corresponding to the molecular mass of active MT1-MMP, was observed in the wildtype fibroblasts (lane 2). Unstimulated and PMA-stimulated human HT1080 fibrosarcoma cells (lanes 3 and 4, respectively), CHO cells transfected with cDNAs encoding MT1-MMP (lane 5), MT2-MMP (lane 6), and MT3-MMP (lane 7), and untransfected CHO cells (lane 8). Equal numbers of successfully transfected cells were analyzed for lanes 5–7. The electrophoretic migration of molecular mass marker proteins is indicated (kDa), along with the predicted migration of MT1-MMP and proMT1-MMP.

mAb 9E8 Inhibits the MT1-MMP-catalyzed Activation of proMMP-2—To study any effect of the antibody on the function of MT1-MMP, we first examined the effect of mAb 9E8 on proMMP-2 activation, using a cellular proMMP-2 activation assay with HT1080 cells. These cells express both MT1-MMP and proMMP-2 (40). When cultured in serum-free medium, HT1080 cells secrete proMMP-2, which can be visualized by gelatin zymography as a ~70 kDa gelatinolytic component (Fig. 2A, lane 1). Upon stimulation of cells with PMA, proMMP-2 is processed into the active enzyme through an intermediate form (41, 42) (lane 2). This activation process is dependent on MT1-MMP, which could also be specifically detected in the PMA stimulated cells by mAb 9E8, as noted above. Accordingly, proMMP-2 activation could be fully inhibited by galardin, a broad spectrum MMP inhibitor, as well as the physiological MT1-MMP inhibitor TIMP-2 (lanes 3 and 5). The first cleavage step was insensitive to TIMP-1, an inhibitor which does not bind to MT1-MMP but efficiently blocks MMP-2 activity (lane 4). However, addition of TIMP-1 did lead to inhibition of the second cleavage event. These observations are in accordance with previous studies demonstrating that the cleavage generating the intermediate form is catalyzed by MT1-MMP, whereas the second cleavage reaction results from MMP-2 autocatalytic cleavage (41, 42).

Very strikingly, addition of mAb 9E8 completely inhibited the proMMP-2 activation process, resulting in a situation identical to that observed with galardin and TIMP-2 (lane 6). The addition of an isotype-matched control antibody (a-TNP) or another mAb against murine MT1-MMP (mAb-2) had no effect on the activation process, demonstrating that the effect observed with mAb 9E8 was neither an artifact resulting from the addition of exogenous IgG or a result of generally targeting MT1-MMP on the cell surface (lanes 7 and 8).

An analysis of the concentration dependence revealed detectable inhibition of the activation reaction with 10–20 nM mAb 9E8 and almost complete inhibition at 60–80 nM (Fig. 2B). For comparison, the kinetics of the interaction of the mAb with purified MT1-MMP were determined by surface plasmon resonance analysis (Fig. 2C). The $K_d$ derived from the kinetic data obtained was between 0.5 and 1 nM (Fig. 2C). Thus, mAb 9E8 inhibited the proMMP-2 activation reaction in concentrations 10–50-fold higher than the actual $K_d$ of the interaction with MT1-MMP. Considering the fact that the conditions of

boundary. The number of microvessel-grid intersections was then counted and plotted versus the distance from the ring to determine microvessel distribution. At least 5 images per experimental condition were used. The lymphatic sprouting assay was performed twice, using independent duct isolates, yielding identical results.
the proMMP-2 activation assay included long-term incubation of the antibody with live PMA-stimulated cells, we considered this to be a highly efficient functional effect.

**mAb 9E8 Has No Effect on the General Proteolytic or the Collagenolytic Activity of MT1-MMP and Shows Weak Interference with TIMP-2 Binding**—Next, we investigated whether the inhibitory effect of mAb 9E8 was restricted to the proMMP-2 activation process or also included inhibition of other MT1-MMP functions.

First, the antibody ability to inhibit the general endopeptidase activity of MT1-MMP was investigated. To this end, the activity of recombinant MT1-MMP was measured using a quenched fluorescent peptide substrate (Fig. 3A). The cleavage of this substrate was fully inhibited by galardin. In contrast, no inhibitory effect of mAb 9E8 was observed, demonstrating that the antibody is not a general inhibitor of MT1-MMP activity.

Second, because an important role of MT1-MMP is the ability to cleave fibrillar collagens directly, we wanted to test whether mAb 9E8 had any effect on this activity. For that purpose, a cell-based collagen degradation assay was utilized (2). In this assay, MT1-MMP expressing, primary mouse fibroblasts are cultured upon a reconstituted collagen type I matrix for 5 days. During this period the fibroblasts degrade the underlying matrix and, as previously demonstrated (2) (25), this degradation process is completely dependent on MT1-MMP since fibroblasts isolated from MT1-MMP-deficient littermate mice lack the ability to degrade the matrix (Fig. 3B). As expected, galardin fully inhibited the collagenolytic activity of the wild-type fibroblasts. In contrast, mAb 9E8 had no effect on the degradation process (Fig. 3B). Furthermore, a quantitative variant of the assay was developed by incorporation of radiolabeled collagen into the matrix. In this way, the degradation process could be followed over time by measuring the release of radioactivity into the surrounding medium. In accordance with the results obtained in the original assay, the accumulation of radioactivity in the conditioned medium displayed a clear MT1-MMP dependence and was fully inhibited by galardin but was not affected by mAb 9E8 (Fig. 3C).

A third functional interaction of MT1-MMP is the binding to TIMP-2. In terms of extracellular proteolysis, the consequences of this interaction are quite complex, depending on the local concentrations of the reactants. Thus, TIMP-2 is capable of

![Image](image_url)
inhibiting the proteolytic activity of MT1-MMP but is also an essential component of the MT1-MMP:TIMP-2:proMMP-2 activation complex involved in MT1-MMP-dependent proMMP-2 activation (43). In this trimolecular complex, TIMP-2 acts as a bridging entity between proMMP-2 and MT1-MMP. Because in this complex MT1-MMP acts as a docking device and is inactivated through the binding of TIMP-2, a neighboring “TIMP-2 free” MT1-MMP molecule serves to mediate the proteolytic cleavage of the bound proMMP-2 (40, 44, 45). Therefore, the TIMP-2 concentration is a crucial determinant for the level of proMMP-2 activation. At low concentrations, TIMP-2 facilitates the activation reaction, whereas at high TIMP-2 concentrations no activation is observed due to the lack of inhibitor free MT1-MMP (46).

Consequently, we studied any interference of mAb 9E8 with the TIMP-2-mediated inhibition of MT1-MMP (Fig. 4). For this purpose, we utilized the above mentioned quenched fluorescent peptide substrate to assay MT1-MMP activity in the presence of the inhibitor. In the first experiment, we employed a TIMP-2 concentration (100 nM) resulting in almost complete inhibition of MT1-MMP activity. As seen in Fig. 4A, addition of mAb 9E8 to this system had no impact on the effect of TIMP-2. Thus, at least under these conditions, the antibody is incapable of preventing the access of the inhibitor to the active site of the enzyme.

This, however, did not exclude a weak interference with the formation of the inhibitor complex that might be apparent only at low concentrations of TIMP-2. To study this possibility, we first established a TIMP-2 concentration range resulting in par-
tial inhibition of MT1-MMP activity (data not shown). We then used conditions leading to ~60% inhibition to study any interference of mAb 9E8 with the effect of the inhibitor (Fig. 4B). Interestingly, under these conditions, we could indeed observe a partial rescue effect of the antibody on the inhibition profile. The lack of complete rescue, even at a high antibody concentration, indicates that this is only a weak effect. Nevertheless, a weak interference with TIMP-2 binding may contribute to explain the inhibitory function of mAb 9E8 against proMMP-2 activation because this interference would counteract the build-up of the proMMP-2 activator complex.

**mAb 9E8 Delays Lymphatic Endothelial Cell Outgrowth in Collagen**—Having characterized the ability of mAb 9E8 to block a single function of MT1-MMP, we next wanted to utilize this as a strategy to differentiate between the different functions of the protease in a matrix-dependent cellular system. The migration of lymphatic endothelial cells (LECs) into 3-dimensional collagen matrices is dependent on proteolytic activity (47) and MMP-2 has been shown to play a major role in this process (16). This opens the question whether the proteolytic cascade step of MT1-MMP catalyzed pro-MMP-2 activation is involved. In particular, this question is important because other proteases may also serve to activate pro-MMP-2 (4, 25). To study this question, we first employed a simple system with spheroids of cultured LECs (HTERT-HDLEC) embedded in a collagen gel. The outgrowth of these cells can be followed microscopically and quantified in an established computerized system (16). When cellular outgrowth was followed in the presence of mAb 9E8, a marked reduction in migration was noted, relative to cells cultured in the presence of an irrelevant control antibody (Fig. 5). Thus, the migration of these cells was indeed supported by the MT1-MMP-proMMP-2 cascade activation.

Finally, to study this phenomenon in a more complex biological system, we employed an established ex vivo system, the “lymphatic ring assay” using explants from mouse thoracic ducts. When cultured in a collagen gel in the presence of serum, these explants expand into the surroundings in the form of tubular outgrowths that retain the characteristics of lymphatic microvessels (15). When mAb 9E8 was added to these cultures, a marked reduction in lymphatic sprouting was noted (Fig. 6), in accordance with the previously reported importance of MMP-2 activity in this process (16). This result shows that the responsible mechanism is indeed MT1-MMP-mediated proMMP-2 activation.

**DISCUSSION**

In this study, we have developed and utilized an MT1-MMP monoclonal antibody that selectively inhibits the complicated process of proMMP-2 activation. To our knowledge, this is the first example of an approach enabling the complete and selective blocking of a single function of a single MMP.

The understanding and prevention of dysregulated MMP activity during pathological processes such as cancer invasion is a subject of extraordinary interest. However, it has become evident that the wide spectrum of MMPs, some with overlapping function and others with opposing roles, complicates both understanding and successful intervention (49). Today, it is clear that the apparent failure of premature clinical trials in this regard was due, at least in part, to a lack of selectivity in the intervention strategies utilized (50). Consequently, current efforts are focused on the development of highly specific reagents, directed against single MMPs (51, 52). An additional level of complexity arises because some of these enzymes have multiple substrates and functional roles (53), which may necessitate the development of even more narrow, function-specific strategies of intervention. Our current work demonstrates that this type of strategy can indeed be pursued.

MT1-MMP is a particularly attractive target in the development of anti-invasive therapy because this protease has a well-established function in matrix degradation (2) and a central role in invasive growth, being expressed by both tumor and stromal cells (48, 54). Whereas tumor studies in genetically based mouse cancer models are hampered by the severe phenotype of MT1-MMP-deficient mice (20), a mAb has recently been developed which efficiently blocks MT1-MMP activity and transplanted tumor growth in vivo (19). However, the exact mechanism through which MT1-MMP serves to promote tumor progression in these systems is not clear. Thus, whereas MT1-MMP was first discovered as the result of the search for the
endogenous activator of the MMP-2 proenzyme (9), the enzyme was subsequently also demonstrated to display direct activity against various ECM proteins, including native collagens (7, 8).

Since then, both the MT1-MMP-dependent proMMP-2 activation and the activity of MT1-MMP toward collagens have been studied extensively. However, although both of these functions appear to be important, their individual contributions to physiological and pathological processes are still insufficiently known. Nevertheless, several observations suggest that MT1-MMP-mediated proMMP-2 activation plays an important role, both during normal development and in disease progression (2, 4, 10–13, 19–23).

The novel MT1-MMP antibody, mAb 9E8, inhibits MT1-MMP-mediated activation of proMMP-2 on the cell surface. Although the mechanism of inhibition is unknown, our studies suggest that a weak interference with the MT1-MMP:TIMP-2 interaction could contribute to this effect, since it may counteract the formation of the MT1-MMP:TIMP-2:proMMP-2 complex involved in the activation process.

The fact that mAb 9E8 has no effect on the general proteolytic or the collagenolytic activity of MT1-MMP provides a unique opportunity to discriminate between the effects of MT1-MMP exerted through the activation of proMMP-2 and those exerted by direct proteolytic attack on ECM components. We have utilized this property to demonstrate the importance of the current enzyme system in two experimental settings with sprouting of lymphatic endothelial cells in a collagen matrix. Importantly, these findings do not only provide independent proof of the importance of MMP-2 in this process but also directly identifies the involvement of the MT1-MMP-proMMP-2 activation reaction.

The specific inhibitory properties of mAb 9E8 complement those of other interesting targeting reagents. These include the above-mentioned neutralizing mAb against MT1-MMP, developed by Devy et al., which completely blocks all proteolytic

**FIGURE 6.** mAb 9E8 delays the sprouting of lymphatic vessels ex vivo. The sprouting of murine thoracic duct explants was followed in the presence of mAb 9E8 or control antibody (mAb against TNP), as indicated. Micrographs show the explant outgrowth in a collagen matrix after 7 days (A) and 11 days (B). Bar, 500 μm. Duplicate samples are shown. Computerized quantification is shown to the right of each panel. *N*, number of microvessel intersections with the grid at increasing distances; see "Experimental Procedures."
activity of the enzyme (19), as well as the more recently described antibody developed by Basu et al., which displays an interference with the collagenolytic function alone (29). Furthermore, mAb 9E8 has a broad potential utility since it reacts with both murine and human MT1-MMP. This is a valuable property since antibodies with cross-species reactivity can be used, e.g. in mouse models with transplanted human tumor cells, to target antigens expressed by both tumor and stromal cells.

Altogether, the specific mechanism of proMMP-2 activation has enabled its selective targeting through the current strategy, leading to a complete blocking of this function of MT1-MMP while leaving all of its other functions intact. Through the complete and selective blocking of a single function of a multifunctional protease, mAb 9E8 may provide the first example of a new generation of MMP inhibitors.

Acknowledgments—We thank Katharina H. Stegmann, Suzanne K. Möller, and Mette M. Nebbelunde for excellent technical assistance. Professor G. Murphy is thanked for the generous gift of TIMP-1.

REFERENCES

1. Murphy, G., and Nagase, H. (2008) Progress in matrix metalloproteinase research. Mol. Aspects Med. 29, 290–308
2. Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S. A., Mankani, M., Robey, P. G., Poole, A. R., Pidoux, I., Ward, J. M., and Birkedal-Hansen, H. (1999) MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81–92
3. Sabe, F., Ota, I., Holmbeck, K., Birkedal-Hansen, S., Solovay, P., Balbin, M., Lopez-Otin, C., Shapiro, S., Inada, M., Krane, S., Allen, E., Chung, D., and Weiss, S. J. (2004) Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell Biol. 167, 769–781
4. Zhou, Z., Apte, S. S., Soininen, R., Cao, R., Baaklini, G. Y., Rauser, R. W., Wang, J., Cao, Y., and Tryggvason, K. (2000) Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. U.S.A. 97, 4052–4057
5. Winchester, P., Grossman, H., Lim, W. N., and Danes, B. S. (1969) A new acid mucopolysaccharidosiis with skeletal deformities simulating rheumatoid arthritis. Am. J. Roentgenol. Radium. Ther. Nucl. Med. 106, 121–128
6. Evans, B. R., Mosig, R. A., Lobl, M., Martignetti, C. R., Camacho, C., Grum-Tokars, V., Glücksmann, M. J., and Martignetti, J. A. (2012) Mutation of membrane-type-1 matrix metalloproteinase, MT1-MMP, causes the multicentric osteolysis and arthritis disease Winchester syndrome. Am. J. Hum. Genet. 91, 572–576
7. d’Ortho, M. P., Will, H., Atkinson, S., Butler, G., Messent, A., Gavrilon, J., Smith, B., Timpl, R., Zardi, L., and Murphy, G. (1997) Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur. J. Biochem. 250, 751–757
8. Ohuchii, E., Imai, K., Fuji, Y., Sato, H., Seiki, M., and Okada, Y. (1997) Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem. 272, 2446–2451
9. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 61–65
10. Martignetti, J. A., Aqeel, A. A., Sewairi, W. A., Boumah, C. E., Kambouris, M., Mayouf, S. A., Sheth, K. V., Eid, W. A., Dowling, O., Harris, J., Glucksman, M. J., Bahabri, S., Meyer, B. F., and Desnick, R. J. (2001) Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat. Genet. 28, 261–265
Targeting MT1-MMP

26. Madsen, D. H., Engelholm, L. H., Ingvarsen, S., Hillig, T., Wagenaar-Müller, R. A., Kjeller, L., Gárdsvoll, H., Hoyer-Hansen, G., Holmbeck, K., Bugge, T. H., and Behrendt, N. (2007) Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation. J. Biol. Chem. 282, 27037–27045

27. Madsen, D. H., Ingvarsen, S., Jürgensen, H. J., Melander, M. C., Kjøller, L., Moyer, A., Honoré, C., Madsen, C. A., Garred, P., Burgdorf, S., Bugge, T. H., Behrendt, N., and Engelholm, L. H. (2011) The non-phagocytic route of collagen uptake: a distinct degradation pathway. J. Biol. Chem. 286, 26996–27010

28. Weiner, L. M., Surana, R., and Wang, S. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317–327

29. Basu, B., Correa de, Sampail, P., Mohammed, H., Fogarasi, M., Corrie, P., Watkins, N. A., Smethurst, P. A., English, W. R., Ouwehand, W. H., and Murphy, G. (2012) Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. Int. J. Biochem. Cell Biol. 44, 393–403

30. Shulman, M., Wilde, C. D., and Kühler, G. (1978) A better cell line for recombinant interferon-gamma secreted by Chinese hamster ovary-320 cells cultivated in suspension in protein-free medium. J. Cell Biol. 79, 16098 –16103

31. Almholt, K., Juncker-Jensen, A., Laerum, O. D., Danø, K., Jørgensen, M., Petersen, C. B., Jansson, A., Jørgensen, T. J., Poulsen, F. M., and Ploug, M. (2007) Generation of recombinant somatomedin-B domain from vitronectin produced in Pichia pastoris. Protein Sci. 16, 1934–1945

32. Kjaergaard, M., Gárdsvoll, H., Hirschberg, D., Niello, S., Mayasuandari, A., Peterson, C. B., Jansson, A., Jørgensen, T. J., Poulsen, F. M., and Ploug, M. (2007) Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris. Protein Sci. 16, 1934–1945

33. Madsen, D. H., Ingvarsen, S., Jürgensen, H. J., Melander, M. C., Gárdsvoll, H., Pehrsson, L., Engelholm, L. H., and Behrendt, N. (2011) A novel functional role of collagen glycosylation: interaction with the endocytic collagen receptor upar/ENDO180. Nat. Struct. Mol. Biol. 17, 202–207

34. Almholt, K., Juncker-Jensen, A., Laerum, O. D., Dane, K., Johnsen, M., Lund, L. R., and Remer, I. (2008) Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model. Mol. Cancer Ther. 7, 2758–2767

35. Basile, J. R., Holmbeck, K., Bugge, T. H., and Gutkind, J. S. (2007) MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J. Biol. Chem. 282, 6899–6905

36. Wall, M. A., Socolich, M., and Ranganathan, R. (2000) The structural basis for red fluorescence in the tetrameric GFP homolog DsRed. Nat. Struct. Biol. 7, 1133–1138

37. List, K., Hoyer-Hansen, G., Renne, E., Danø, K., and Behrendt, N. (1999) Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. J. Immunol. Methods 222, 125–133

38. Nisato, R. E., Harrison, J. A., Buser, R., Orlic, L., Rinsch, C., Montesano, R., Dupraz, P., and Pepper, M. S. (2004) Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span. Am. J. Pathol. 165, 11–24

39. Mols, J., Peeters-Joris, C., Wattiez, R., Agathos, S. N., and Schneider, Y. J. (2005) Recombinant interferon-gamma secreted by Chinese hamster ova- ry-320 cells cultivated in suspension in protein-free media is protected against extracellular proteolysis by the expression of natural protease inhibitors and by the addition of plant protein hydrolysates to the culture medium. In Vitro Cell Dev. Biol. Anim. 41, 83–91

40. Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., and Goldberg, G. I. (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270, 5331–5338

41. Atkinson, S. I., Crabbe, T., Cowell, S., Ward, R. V., Butler, M. J., Sato, H., Seikí, M., Reynolds, J. I., and Murphy, G. (1995) Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J. Biol. Chem. 270, 30479–30485

42. Strongin, A. Y., Marmer, B. L., Grant, G. A., and Goldberg, G. I. (1993) Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J. Biol. Chem. 268, 14033–14039

43. Kodama, T., Sato, H., Fukui, E., Naiki, K., Okada, Y., and Seiki, M. (1998) TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J. Biol. Chem. 273, 16098–16103

44. Butler, G. S., Butler, M. J., Atkinson, S. I., Will, H., Tamura, T., Schade Vanwestrum, S., Crabbe, T., Clements, J., d’Ortho, M. P., and Murphy, G. (1998) The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. A kinetic study. J. Biol. Chem. 273, 871–880

45. Itoh, Y., Takamura, A., Itu, N., Maru, Y., Sato, H., Sunaga, N., Aoki, T., and Seiki, M. (2001) Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J. 20, 4782–4793

46. Bigg, H. F., Morrison, C. J., Butler, G. S., Bogoyevitch, M. A., Wang, Z., Soloway, P. D., and Overall, C. M. (2001) Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1 matrix metalloproteinase. Cancer Res. 61, 3610–3618

47. Matsu, M., Sakurai, K., Koizumi, K., and Saiki, I. (2007) Curcumin inhibits the formation of capillary-like tubes by rat lymphatic endothelial cells. Cancer Lett. 251, 288–295

48. Polette, M., Nawrocki, B., Gilles, C., Sato, H., Seiki, M., Tournier, J. M., and Birembaut, P. (1996) MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch. 428, 29–35

49. Overall, C. M., and Kleifeld, O. (2006) Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer. 6, 227–239

50. Coussens, L. M., Fingleton, B., and Matrisian, L. M. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392

51. Devy, L., and Dransfield, D. T. (2011) New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies. Biochem. Res. Int. 2011, 191670

52. Naito, S., Takahashi, T., Onoda, J., Yamauchi, A., Kawai, T., Kishino, J., Yamane, S., Fujii, I., Fukui, N., and Numata, Y. (2012) Development of a monoclonal antibody specific for the active form of matrix metalloproteinase-13. Biochemistry 51, 8877–8884

53. Egeblad, M., and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161–174

54. Okada, A., Bellocq, J. P., Rouyer, N., Chenard, M. P., Rio, M. C., Chambron, P., and Basset, P. (1995) Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc. Natl. Acad. Sci. U.S.A. 92, 2730–2734